- Home
- EMN vs MRNA Comparison
EMN vs MRNA Comparison
Compare EMN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMN
- MRNA
- Stock Information
- Founded
- EMN 1920
- MRNA 2010
- Country
- EMN United States
- MRNA United States
- Employees
- EMN N/A
- MRNA N/A
- Industry
- EMN Major Chemicals
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMN Industrials
- MRNA Health Care
- Exchange
- EMN Nasdaq
- MRNA Nasdaq
- Market Cap
- EMN 9.2B
- MRNA 10.6B
- IPO Year
- EMN 1993
- MRNA 2018
- Fundamental
- Price
- EMN $78.33
- MRNA $26.56
- Analyst Decision
- EMN Buy
- MRNA Hold
- Analyst Count
- EMN 13
- MRNA 19
- Target Price
- EMN $99.46
- MRNA $48.13
- AVG Volume (30 Days)
- EMN 1.8M
- MRNA 14.2M
- Earning Date
- EMN 07-24-2025
- MRNA 05-01-2025
- Dividend Yield
- EMN 4.24%
- MRNA N/A
- EPS Growth
- EMN 1.14
- MRNA N/A
- EPS
- EMN 7.86
- MRNA N/A
- Revenue
- EMN $9,362,000,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- EMN N/A
- MRNA N/A
- Revenue Next Year
- EMN $3.35
- MRNA $8.98
- P/E Ratio
- EMN $9.98
- MRNA N/A
- Revenue Growth
- EMN 2.79
- MRNA N/A
- 52 Week Low
- EMN $70.90
- MRNA $23.15
- 52 Week High
- EMN $114.50
- MRNA $158.82
- Technical
- Relative Strength Index (RSI)
- EMN 43.74
- MRNA 50.60
- Support Level
- EMN $79.54
- MRNA $25.22
- Resistance Level
- EMN $82.83
- MRNA $27.15
- Average True Range (ATR)
- EMN 1.86
- MRNA 1.61
- MACD
- EMN 0.05
- MRNA 0.26
- Stochastic Oscillator
- EMN 10.14
- MRNA 47.66
About EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.